Stock Track | Personalis Soars 5.24% After-Hours on Positive Analyst Ratings and Price Target Boost

Stock Track11-12

Personalis (PSNL) stock surged 5.24% in after-hours trading on Tuesday, following a series of positive analyst ratings and a significant price target increase. The company, which specializes in advanced genomics for cancer, saw its shares climb as multiple financial firms reaffirmed their confidence in its potential.

Leading the bullish sentiment, H.C. Wainwright raised its price target on Personalis to $13 from $10, maintaining a Buy rating. The firm's decision came after Personalis received undisclosed positive news, suggesting potential developments that could drive future growth. This substantial increase in the price target indicates a strong vote of confidence in the company's prospects.

Adding to the positive outlook, several other prominent financial institutions maintained their Buy ratings on Personalis stock. Guggenheim and BTIG both reaffirmed their Buy ratings, while Morgan Stanley maintained an Equal-Weight stance. This consensus among analysts suggests a generally optimistic view of the company's future performance and market position.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1193372735?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 05:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1193372735","market":"us","top_or_hot":-1,"title":"Stock Track | Personalis Soars 5.24% After-Hours on Positive Analyst Ratings and Price Target Boost","media":"Stock Track","content":"<p>Personalis (PSNL) stock surged 5.24% in after-hours trading on Tuesday, following a series of positive analyst ratings and a significant price target increase. The company, which specializes in advanced genomics for cancer, saw its shares climb as multiple financial firms reaffirmed their confidence in its potential.</p>\n\n<p>Leading the bullish sentiment, H.C. Wainwright raised its price target on Personalis to $13 from $10, maintaining a Buy rating. The firm's decision came after Personalis received undisclosed positive news, suggesting potential developments that could drive future growth. This substantial increase in the price target indicates a strong vote of confidence in the company's prospects.</p>\n\n<p>Adding to the positive outlook, several other prominent financial institutions maintained their Buy ratings on Personalis stock. Guggenheim and BTIG both reaffirmed their Buy ratings, while Morgan Stanley maintained an Equal-Weight stance. This consensus among analysts suggests a generally optimistic view of the company's future performance and market position.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Personalis Soars 5.24% After-Hours on Positive Analyst Ratings and Price Target Boost</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Personalis Soars 5.24% After-Hours on Positive Analyst Ratings and Price Target Boost\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-12 05:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Personalis (PSNL) stock surged 5.24% in after-hours trading on Tuesday, following a series of positive analyst ratings and a significant price target increase. The company, which specializes in advanced genomics for cancer, saw its shares climb as multiple financial firms reaffirmed their confidence in its potential.</p>\n\n<p>Leading the bullish sentiment, H.C. Wainwright raised its price target on Personalis to $13 from $10, maintaining a Buy rating. The firm's decision came after Personalis received undisclosed positive news, suggesting potential developments that could drive future growth. This substantial increase in the price target indicates a strong vote of confidence in the company's prospects.</p>\n\n<p>Adding to the positive outlook, several other prominent financial institutions maintained their Buy ratings on Personalis stock. Guggenheim and BTIG both reaffirmed their Buy ratings, while Morgan Stanley maintained an Equal-Weight stance. This consensus among analysts suggests a generally optimistic view of the company's future performance and market position.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PSNL","symbol_name":"Personalis","start_time":0,"source_url":"","article_id":"1193372735","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1193372735","pubTimestamp":1762898305,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Personalis (PSNL) stock surged 5.24% in after-hours trading on Tuesday, following a series of positive analyst ratings and a significant price target increase. The company, which specializes in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PSNL":"Personalis"},"translate_title":"个股追踪|Personalis盘后飙升5.24%，因分析师积极评级和目标价上调","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PSNL":1},"content_text":"Personalis (PSNL) stock surged 5.24% in after-hours trading on Tuesday, following a series of positive analyst ratings and a significant price target increase. The company, which specializes in advanced genomics for cancer, saw its shares climb as multiple financial firms reaffirmed their confidence in its potential.\nLeading the bullish sentiment, H.C. Wainwright raised its price target on Personalis to $13 from $10, maintaining a Buy rating. The firm's decision came after Personalis received undisclosed positive news, suggesting potential developments that could drive future growth. This substantial increase in the price target indicates a strong vote of confidence in the company's prospects.\nAdding to the positive outlook, several other prominent financial institutions maintained their Buy ratings on Personalis stock. Guggenheim and BTIG both reaffirmed their Buy ratings, while Morgan Stanley maintained an Equal-Weight stance. This consensus among analysts suggests a generally optimistic view of the company's future performance and market position.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1193372735","isCrawlerRequest":true}